The Obesity Pill Market Shift: A Global Opportunity Beckons

Bank of America’s recent price target increase for Eli Lilly (LLY) stock has drawn attention to an often-overlooked aspect of the company’s business: its growing presence in international obesity markets. For years, the US has dominated Lilly’s sales, but a new trend is emerging that could potentially outsize domestic revenues.

The global growth of GLP-1 drugs, used to treat both diabetes and obesity by curbing appetite, is driving this shift. These medications have gained significant traction worldwide, with Mounjaro, Lilly’s diabetes injection, posting impressive gains in Europe (55%), Japan (30%), and China (93%) last quarter.

Lilly’s new oral GLP-1 pill, Foundayo, presents a unique opportunity for the company to reach patients who may be deterred by weekly injections. This demographic has historically been difficult for Lilly’s other treatments to engage, but with Foundayo, the company can now offer an alternative solution that could propel its global obesity sales beyond domestic levels.

Bank of America’s price target increase to $1,344 from $1,334 is based on an updated 2027 earnings estimate that removes one-time research charges. The bank’s analysis demonstrates faith in Lilly’s ability to outperform its peers by applying a multiple of 28.5 times to estimated earnings.

The US market for obesity medications has long been dominated by Eli Lilly, but this dominance is slowly eroding as the international scene offers a more level playing field. Many countries have far higher rates of untreated patients than the US, providing an opportunity for Lilly’s GLP-1 sales to continue growing.

As investors reassess their positions on the stock, the shift in focus from domestic obesity sales to international opportunities may seem subtle but speaks volumes about the company’s long-term prospects. With Bank of America’s price target increase and Lilly’s growing global presence, now is an opportune time for investors to reconsider their investments.

Lilly’s ability to adapt to changing market conditions has been a hallmark of its success. As the global obesity market continues to evolve, one thing is certain: Eli Lilly will be at the forefront of this shift.